ONWARD MEDICAL


Associated tags: Quality of life, Spinal cord, Health, FDA, Movement, Tetraplegia, Spinal cord stimulator, Science, Euronext, ARC, SCI, Medical device, Research, Pharmaceutical industry, Nature, BCI

Locations: SWITZERLAND, USA, NORTH AMERICA, US, MIAMI, LOVELL, NIJMEGEN, NEVADA, EINDHOVEN, NL, NETHERLANDS, UNITED STATES, EUROPE, CANADA

ONWARD Announces Participation at Upcoming Events in October

Retrieved on: 
Thursday, September 29, 2022
Science, Neurology, Biotechnology, Research, Physical Therapy, Health, Medical Devices, Health Technology, Health, Marver, Movement, High Tech Campus Eindhoven, U.S. FDA, Spinal cord, Spinal cord injury, Nature, Company, CEO, Technology, Quality of life, Science, ARC, Medical device, Risk management

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.

Key Points: 
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARD has received three Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IMand ARC-EX.
  • These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD Reports First Half 2022 Financial and Operating Results

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, Health, Surgery, Medical Devices, Income, Health, European Innovation Council, Movement, High Tech Campus Eindhoven, U.S. FDA, Spinal cord, McKinsey & Company, Spinal cord injury, Hemiunu, EDT, State Administrative Expenses, News, Nature, Company, Public, SCI, Patient, Government, Investment, Business, Forward-looking statement, Technology, SME, Quality of life, CLA, General officer, University of Virginia Darden School of Business, CET, Science, ARC, Marketing, RVO, University, Webcast, Medical device, Film, Bank, Pharmaceutical industry, EU, EUR, Euronext

Total Operating Expenses increased during H1 2022 by EUR 6,3 million to EUR 16,1 million.

Key Points: 
  • Total Operating Expenses increased during H1 2022 by EUR 6,3 million to EUR 16,1 million.
  • The decrease in cash of EUR 12,6 million compared to 31 December 2021 is due to cash outflows mainly for operating activities.
  • ONWARDs management expects to continue the steady and consistent execution of its strategy in the second half of 2022 and beyond.
  • Also in the second half of 2022, the Company expects to release combined top-line data from the STIMO-HEMO and HemON studies.

ONWARD Announces Appointment of Vivian Riefberg to Board of Directors

Retrieved on: 
Monday, September 26, 2022
Biotechnology, Health, Surgery, Medical Devices, Dutch public broadcasting system, Movement, McKinsey & Company, PBS, Nature, Public, Harvard Business School, Industry, Business, Davos, Government, Technology, University of Virginia Darden School of Business, Leadership, ARC, NIH, Child, U.S. FDA, Spinal cord injury, PHA, Financial compensation, Company, Obesity, Intellectual property, History, High Tech Campus Eindhoven, Science, Partnership, Spinal cord, First Lady Michelle Obama (painting), Radcliffe College, Forward-looking statement, Board of directors, Board, Health, American, Publication, Johns Hopkins School of Medicine, Quality of life, Solution, Uncertainty, Darden, World Economic Forum, Multimedia, University, Euronext, Management, Pharmaceutical industry, Medical device

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced the appointment of Vivian Riefberg as a non-executive member of its Board of Directors.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced the appointment of Vivian Riefberg as a non-executive member of its Board of Directors.
  • Her appointment to the Board will be presented for shareholder approval at the next Annual General Meeting.
  • View the full release here: https://www.businesswire.com/news/home/20220926005494/en/
    Vivian Riefberg joins the ONWARD Medical Board of Directors (Photo: Business Wire)
    Vivian Riefberg is a distinguished expert in health care, government, and strategy.
  • ONWARD has the opportunity to build a very special enterprise that is both successful and impactful, said Vivian Riefberg.

ONWARD to Release Half-Year 2022 Financial Results and Host Webcast on September 27, 2022

Retrieved on: 
Wednesday, September 21, 2022
Software, Biotechnology, Finance, Hardware, Health, Medical Devices, Professional Services, Technology, Health, Movement, High Tech Campus Eindhoven, U.S. FDA, Spinal cord, Spinal cord injury, Nature, Company, Forward-looking statement, Technology, Quality of life, Science, ARC, Webcast, Euronext, Medical device, Broadcasting, Health insurance, Risk management

Management will host a webcast to discuss operational and financial highlights, as well as provide a business update on September 27, 2022, at 16:00 CEST/10:00 EDT.

Key Points: 
  • Management will host a webcast to discuss operational and financial highlights, as well as provide a business update on September 27, 2022, at 16:00 CEST/10:00 EDT.
  • Participants may also join by phone:
    A recording of the webcast will be available on the Companys website following the live event.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD Reports Positive Topline Results from a Pivotal Study to Restore Arm and Hand Function in People With Spinal Cord Injury

Retrieved on: 
Tuesday, September 13, 2022
Health, Medical Devices, Surgery, Physical Therapy, Other Science, Research, Science, Safety, Movement, Christopher and Dana Reeve Foundation, Research, Sensation, Nature, Electricity, Infection, Emory University School of Medicine, Paralysis, PT, Technology, Computer engineering, ARC, Shepherd Center, Time, U.S. FDA, Spinal cord injury, Company, High Tech Campus Eindhoven, Science, University of Washington Department of Bioengineering, Assessment, SCI, Spinal cord, FDA, Review, Forward-looking statement, Hand, Incontinence, Prehensility, Health, Doctor of Philosophy, Department, Loss of Sensation, Quality of life, Physical medicine and rehabilitation, Ascending limb of loop of Henle, Grade, University, Euronext, Trapping, Pharmaceutical industry, Medical device, Medicine

ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with movement disabilities.

Key Points: 
  • ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with movement disabilities.
  • Our vision is to empower people with spinal cord injury to enjoy life in every way that matters to them.
  • Todays excellent results from the Up-LIFT study will help us transform that vision into reality, said Dave Marver, ONWARD CEO.
  • We are hopeful we can begin to positively impact the lives of people with spinal cord injury sometime during the second half of 2023.

ONWARD Announces Participation at Upcoming Investor Events in September

Retrieved on: 
Wednesday, September 7, 2022
Professional Services, Health, Surgery, Finance, Managed Care, Biotechnology, Technology, ARC, Hyperreflexia, Science, High Tech Campus Eindhoven, Spinal cord injury, Quality of life, CFO, Movement, Company, FDA, Spinal cord, Health, Nature, Risk management

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.

Key Points: 
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARD has received three Breakthrough Device Designations from the U.S. FDA, encompassing both ARCIM and ARCEX.
  • These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.